<DOC>
	<DOC>NCT00003256</DOC>
	<brief_summary>Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.</brief_summary>
	<brief_title>Flavopiridol in Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES: I. Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate. II. Assess the toxic effects of flavopiridol in this patient population. OUTLINE: Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation. Patients are followed every 3 months until death.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>PATIENT CHARACTERISTICS: Performance Status: ECOG 02 Life Expectancy: At least 3 months WBC at least 3,000/mm3 Absolute neutrophil count at least 1,200/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 8 g/dL Bilirubin no greater than 1.5 mg/dL SGOT no greater than 2.5 times normal Creatinine no greater than 1.5 mg/dL Prostatespecific antigen at least 10 ng/mL (if bone only disease) No prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer No serious medical illness No cord compression symptoms PRIOR CONCURRENT THERAPY: No prior chemotherapy No prior suramin therapy Prior or concurrent use of luteinizing hormonereleasing hormone allowed (no other concurrent hormonal therapy) No prior antiandrogen therapy within 4 weeks of study At least 4 weeks since prior radiotherapy No prior strontium therapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adenocarcinoma of the prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>